Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Summary

This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum containing regimens, and receive treatment with irinotecan liposomes combined with cisplatin or carboplatin regimens.

Timeline

Start

2024-03-15

Primary completion

2025-09-15

Completion

2028-09-15

Drugs

Indications